

Summary of Blood Pressure Change Over 32-Week Dosing Period for ECHO Trial

Summary of Systolic/Diastolic Blood Pressure by Treatment Group

Mean (95% Confidence Interval)

Weeks Post Dose	Systolic Blood Pressure		Diastolic Blood Pressure	
	Investigational Treatment	Placebo	Investigational Treatment	Placebo
0	143.0 (142.0,144.0)	143.1 (142.2,144.0)	103.4 (102.4,104.3)	103.1 (102.1,104.0)
8	141.8 (140.8,142.8)	143.3 (142.4,144.3)	102.1 (101.1,103.1)	102.9 (102.0,103.8)
16	140.2 (139.2,141.3)	143.1 (142.2,144.0)	100.4 (99.4,101.3)	103.1 (102.2,104.0)
24	138.8 (137.8,139.8)	143.0 (142.1,143.9)	98.6 (97.6,99.6)	103.2 (102.3,104.1)
32	137.0 (136.0,138.0)	143.3 (142.4,144.2)	97.2 (96.2,98.1)	103.1 (102.2,104.1)

Notes:

- To be enrolled in the ECHO Trial subjects had to present with SBP \geq 125 and DBP \geq 85 at baseline.
- Treated subjects received 4mg ECHOMAX tablets twice daily over the 32 week dosing period.

